GlaxoSmithKline’s breast cancer drug TYKERB® has recently been approved by the USFDA for advanced or metastatic breast cancer.
In lieu of this approval, GSK confirmed that TYKERB® (lapatinib) will be available through Commitment to Access – the company’s program which provides low income patients with access to GSK products used in an outpatient setting in the United States.
…patients who have been prescribed TYKERB and have no insurance coverage may be eligible to receive TYKERB free of charge if they live in one of the 50 states or the District of Columbia and their income is at or below 500 percent of the federal poverty level.
…patients enrolled in a Medicare Part D plan, eligibility also requires documentation of $600 in expenditures on prescription medicines in the current calendar year.
…patients who are eligible for Medicare and who have incomes below 135 percent of the federal poverty level may not be eligible for GSK's patient assistance programs if they qualify for full assistance under Medicare.
For more information, visit the website: Commitment to Access and by calling 1-866-475-3678.
Read the full report.
Comment Preview